drugset / Trial / NCT06173778

Semaglutide for Post-Smoking Cessation Weight Management

NCT06173778

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

Timeline

Start
2024-04-23
Primary completion
2026-07-01
Completion
2026-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 2.4 mg Subcutaneous
Background Nicotine Unknown 14 mg Other
Background Nicotine Unknown 21 mg Other

Indications